All In Biotech

Drug Trial Radar · NCT05156710

BIVV020 (SAR445088) in Prevention and Treatment of Antibody-mediated Rejection (AMR)

A Multi-cohort, Randomized, Phase 2, Open-label Study to Assess the Preliminary Efficacy, Safety, and Pharmacokinetics of BIVV020 for Prevention and Treatment of Antibody-mediated Rejection in Adult Kidney Transplant Recipients.

Last checked: Nov 19, 2026Latest source record: Aug 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

48

Actual

Start

Jun 9, 2022

Primary completion

Oct 21, 2025

Study completion Oct 20, 2026

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Dec 14, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: * Cohort A: To evaluate the efficacy of BIVV020 in prevention of AMR * Cohort B: To evaluate the efficacy of BIVV020 in treatment of active AMR Secondary Objectives: * To assess the overall efficacy of BIVV020 in prevention or treatment of AMR * To characterize the safety and tolerability of BIVV020 in kidney transplant participants * To characterize the pharmacokinetic (PK) profile of BIVV020 in kidney transplant participants * To evaluate the immunogenicity of BIVV020

Conditions

  • Transplant Rejection

Interventions

  • BIVV020 (SAR445088)Drug

    Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

  • Intravenous immunoglobulin (IVIg)Drug

    Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

  • Rituximab or biosimilarDrug

    Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

  • Antithymocyte globulin (ATG)Drug

    Pharmaceutical Form: Solution for injection Route of Administration: Intravenous

  • TacrolimusDrug

    Pharmaceutical Form: Tablet Route of Administration: Oral

  • MycophenolateDrug

    Pharmaceutical Form: Tablet Route of Administration: Oral

  • CorticosteroidsDrug

    Pharmaceutical Form: Vary Route of Administration: Vary

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohort A: Treatment failure rateTime frame: Up to Week 49
  2. Cohort B: AMR resolution rateTime frame: Up to Week 49

Locations

27 sites in 7 countries. Site status is shown where the registry gives one.

  • Cedars-Sinai Medical Center- Site Number : 8400100

    Los Angeles, California

  • University of California Los Angeles Medical Center- Site Number : 8400103

    Los Angeles, California

  • University of California San Francisco - Parnassus Heights- Site Number : 8400001

    San Francisco, California

  • Massachusetts General Hospital- Site Number : 8400007

    Boston, Massachusetts

  • Brigham & Women's Hospital- Site Number : 8400004

    Boston, Massachusetts

  • NYU Langone Medical Center- Site Number : 8400102

    New York, New York

  • University of Wisconsin Hospitals and Clinics- Site Number : 8400003

    Madison, Wisconsin

  • Investigational Site Number : 1240101

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240001

    Vancouver, British Columbia, Canada

  • Investigational Site Number : 1240002

    London, Ontario, Canada

  • Investigational Site Number : 1240003

    Montreal, Quebec, Canada

  • Investigational Site Number : 2500007

    Bordeaux, France

  • Investigational Site Number : 2500002

    Créteil, France

  • Investigational Site Number : 2500001

    Paris, France

  • Investigational Site Number : 2500005

    Toulouse, France

  • Investigational Site Number : 2760002

    Berlin, Germany

  • Investigational Site Number : 2760004

    Essen, Germany

  • Investigational Site Number : 2760001

    Munich, Germany

  • Investigational Site Number : 3800004

    Bologna, Emilia-Romagna, Italy

  • Investigational Site Number : 3800002

    Rome, Lazio, Italy

  • Investigational Site Number : 3800001

    Brescia, Lombardy, Italy

  • Investigational Site Number : 3800003

    Milan, Milano, Italy

  • Investigational Site Number : 7240004

    Barcelona, Barcelona [Barcelona], Spain

  • Investigational Site Number : 7240003

    Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7240002

    Madrid, Madrid, Comunidad de, Spain

  • Investigational Site Number : 7520001

    Huddinge, Sweden

  • Investigational Site Number : 7520002

    Uppsala, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.